12
Participants
Start Date
October 31, 2006
Primary Completion Date
January 31, 2011
Study Completion Date
July 31, 2011
Alemtuzumab (CAMPATH 1H) associated to G-CSF
"All patients receive Alemtuzumab in 3 successive phases:~Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.~Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.~Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
Saint Antoine Hospital, Hematology Unit, Paris
Assistance Publique - Hôpitaux de Paris
OTHER